Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2024

Naso Julia, Desai Aakash, Smith Caleb J, Ashara Yash P, Yip Stephen, Lo Ying-Chun

Abstract excerpt

OBJECTIVES: Accurately predicting which patients diagnosed with non-small cell lung cancer (NSCLC) will respond to immunotherapy remains a clinical challenge. This study aims to determine the associations between MYC immunoreactivity, MYC copy number gain (CNG), driver mutations and survival following immunotherapy treatment, to provide insight into whether clinical MYC assessment may have predictive value....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to DNA Copy Number Variations

Share to Immunohistochemistry

Share to Immunotherapy

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 39173231
DOI: 10.1016/j.lungcan.2024.107927

Genes

MYC
KRAS
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.PMID 39173231Read ↗

Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.Semantic proximity Read ↗

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.Semantic proximity Read ↗

Amplification of Extrachromosomal MYC Paralogs Shapes Immunosuppressive Tumor Microenvironment in Small Cell Lung CancerSemantic proximity Read ↗

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.Semantic proximity Read ↗

C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug TargetSemantic proximity Read ↗

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.Semantic proximity Read ↗

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancerSemantic proximity Read ↗

Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.Semantic proximity Read ↗

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomasSemantic proximity Read ↗

PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapySemantic proximity Read ↗

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung CancerSemantic proximity Read ↗

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.